Global Xerostomia (Dry Mouth Disease) Therapeutics Market Growth (Status and Outlook) 2025-2031
Description
According to this study, the global Xerostomia (Dry Mouth Disease) Therapeutics market size will reach US$ 691 million by 2031.
Xerostomia is a subjective feeling, caused by different reasons, many of the systemic many diseases are complications, some are the result of inevitable development. The side effect of the medicine is also one of the important factors that cause dry mouth. Xerostomia is a condition caused by a lack of saliva in the mouth. The amount of saliva in the mouth depends on the balance between production and consumption. If the amount of saliva produced is less than the amount consumed, there is a negative balance, indicating dry mouth.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LPI (LP Information)' newest research report, the “Xerostomia (Dry Mouth Disease) Therapeutics Industry Forecast” looks at past sales and reviews total world Xerostomia (Dry Mouth Disease) Therapeutics sales in 2024, providing a comprehensive analysis by region and market sector of projected Xerostomia (Dry Mouth Disease) Therapeutics sales for 2025 through 2031. With Xerostomia (Dry Mouth Disease) Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Xerostomia (Dry Mouth Disease) Therapeutics industry.
This Insight Report provides a comprehensive analysis of the global Xerostomia (Dry Mouth Disease) Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Xerostomia (Dry Mouth Disease) Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Xerostomia (Dry Mouth Disease) Therapeutics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Xerostomia (Dry Mouth Disease) Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Xerostomia (Dry Mouth Disease) Therapeutics.
This report presents a comprehensive overview, market shares, and growth opportunities of Xerostomia (Dry Mouth Disease) Therapeutics market by product type, application, key players and key regions and countries.
Segmentation by Type:
Artificial Saliva
Salivary Stimulants
Saliva Substitutes
Drugs
Salivary Pens
Others
Segmentation by Application:
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Acacia Pharma
Church & Dwight
GlaxoSmithKline
Hikma Pharmaceuticals
Lupin
OraCoat
Parnell Pharmaceuticals
Pendopharm
Pfizer
Sun Pharmaceutical Industries
Synedgen
Please note: The report will take approximately 2 business days to prepare and deliver.
Xerostomia is a subjective feeling, caused by different reasons, many of the systemic many diseases are complications, some are the result of inevitable development. The side effect of the medicine is also one of the important factors that cause dry mouth. Xerostomia is a condition caused by a lack of saliva in the mouth. The amount of saliva in the mouth depends on the balance between production and consumption. If the amount of saliva produced is less than the amount consumed, there is a negative balance, indicating dry mouth.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LPI (LP Information)' newest research report, the “Xerostomia (Dry Mouth Disease) Therapeutics Industry Forecast” looks at past sales and reviews total world Xerostomia (Dry Mouth Disease) Therapeutics sales in 2024, providing a comprehensive analysis by region and market sector of projected Xerostomia (Dry Mouth Disease) Therapeutics sales for 2025 through 2031. With Xerostomia (Dry Mouth Disease) Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Xerostomia (Dry Mouth Disease) Therapeutics industry.
This Insight Report provides a comprehensive analysis of the global Xerostomia (Dry Mouth Disease) Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Xerostomia (Dry Mouth Disease) Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Xerostomia (Dry Mouth Disease) Therapeutics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Xerostomia (Dry Mouth Disease) Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Xerostomia (Dry Mouth Disease) Therapeutics.
This report presents a comprehensive overview, market shares, and growth opportunities of Xerostomia (Dry Mouth Disease) Therapeutics market by product type, application, key players and key regions and countries.
Segmentation by Type:
Artificial Saliva
Salivary Stimulants
Saliva Substitutes
Drugs
Salivary Pens
Others
Segmentation by Application:
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Acacia Pharma
Church & Dwight
GlaxoSmithKline
Hikma Pharmaceuticals
Lupin
OraCoat
Parnell Pharmaceuticals
Pendopharm
Pfizer
Sun Pharmaceutical Industries
Synedgen
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
105 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Xerostomia (Dry Mouth Disease) Therapeutics Market Size by Player
- 4 Xerostomia (Dry Mouth Disease) Therapeutics by Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Global Xerostomia (Dry Mouth Disease) Therapeutics Market Forecast
- 11 Key Players Analysis
- 12 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
